# OnCo record nct05987332 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05987332/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05987332", "NCT05987332" ;
  schema:name "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma"@en ;
  schema:alternateName "DAR-UM-2"@en ;
  schema:description "A phase 2/3 trial of Darovasertib, Crizotinib, Pembrolizumab in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05987332/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05987332> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2023-10-31" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/darovasertib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/dacarbazine/> ;
  onco:companies <https://onco.cc/companies/ideaya-biosciences/> .